Lanthanum carbonate Shire

IDrugs

Volumn 6, Issue 7, 2003, Pages 688-695

  Locatelli, Francesco ^a   D'Amico, Marco ^a   Pontoriero, Giuseppe ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; CALCIUM SALT; FERRIC CITRATE; IRON SALT; LANTHANUM; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

ABDOMINAL PAIN; CLINICAL TRIAL; DIALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; NAUSEA; NONHUMAN; PARATHYROIDECTOMY; REVIEW; SECONDARY HYPERPARATHYROIDISM; STRUCTURE ACTIVITY RELATION; VOMITING;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; KIDNEY FAILURE; LANTHANUM; PHOSPHATES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0042165009     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. 174166 Shire focuses on virtual integration. Scrip 1995 2006 12
2. 220712 Major achievements by Shire in its tenth anniversary year. Four projects advanced to the next development phase. Shire Pharmaceuticals Ltd Press Release 1996 September 27
3. 240183 Shire to enter phase II studies with Lambda. Shire Pharmaceuticals Ltd Press Release 1997 March 21
4. 245004 Shire Pharmaceuticals Group plc: Excellent commercial and research and development progress. Shire Pharmaceuticals Group Plc Press Release 1997 May 06
5. 246389 Shire's prospects for chronic fatigue syndrome and renal bone disorder. IDdb author IDDB Meeting Report 1997 May 06
6. 302062 Lanthanum carbonate: A novel non-calcium containing phosphate binder. Dewberry K, Fox JS, Stewart J, Murray JR, Hutchison AJ J Am Soc Nephrol 1997 9 Abs 560A Phase I study demonstrating the efficacy of lanthanum carbonate, as compared to placebo, in reducing urinary phosphorus excretion in healthy volunteers, indicating effective intestinal phosphate binding.
7. 302064 Lanthanum carbonate an effective inhibitor of phosphate absorption from the intestinal tract. Dewberry K, Fox JS, Curtis CG, Murray JR, Hutchinson AJ Nephrol Dial Transplant 1997 12 9 A98 Experimental study showing the efficacy of lanthanum carbonate in reducing radiolabeled intestinal absorption in isolation perfused gut of rats.
8. 304751 Shire Pharmaceuticals Group plc reports STG 6.2 million profit for the nine months ended September 1998. Shire Pharmaceuticals Group Plc Press Release 1998 November 11
9. 329228 Shire reports positive US phase II results for Lambda. Shire Pharmaceuticals Group Plc Press Release 1999 June 24
10. 329493 AnorMED's drug Lambda will proceed to phase III in US after positive phase II results with kidney failure patients. AnorMED Inc Press Release 1999 June 25
11. 360624 Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy. Hutchinson AJ Perit Dial Int 1999 19 Suppl 2 S408-S412 A good review of the treatment of renal osteodystrophy, focusing on new phosphate binders, lanthanum carbonate and Renagel.
12. 360626 Phosphate binders on iron basis: A new perspective? Kidney Int Suppl 1999 73 S42-S45
13. 360635 Safety of an investigational phosphate binder (lanthanum carbonate) in hemodialysis patients. Joy MS, Hladik GA, Finn WF J Am Soc Nephrol 1999 10 263A
14. 360637 Results of a randomized dose-ranging, placebo cotrolled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis. Finn WF, Joy MS, Hladik GA J Am Soc Nephrol 1999 10 261A Lanthanum carbonate efficacy in a phase II study conducted in 145 hemodialysis patients.
15. 366779 Hyperphosphatemia - A silent killer of patients with renal failure. Amann K, Gross ML, London GM, Ritz E Nephrol Dial Transplant 1999 14 9 2085-2087
16. 366782 Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Block GA, Hulbert-Sheron TE, Levin NW, Port FK Am J Kidney Dis 1998 31 4 607-617 An important clinical study directly linking hyperphosphatemia and increased Ca-P product to mortality in hemodialysis patients.
17. 366783 Fracturing dialysis osteodystrophy and dialysis encephalopathy. Parkinson IS, Ward MK, Feest RWP, Kerr DNS 1979 1 8113 406-409 Highlights the risk of long-term aluminium toxicity in dialysis patients, due to use of dialysate containing aluminium (even at very low concentrations).
18. 366784 Reduction of dietary phosphorus absorption by phosphorus binders. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS J Clin Invest 1989 81 1 66-73 A review of phosphate binders, highlighting the risk of hypercalcemia due to calcium-containing phosphate binders.
19. 366786 Renagel, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The Renagel Study Group. Slatopolsky EA, Burke SK, Dillon MA Kidney Int 1999 55 1 299-307
20. 366788 A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption. Graff L, Burnel D Res Comm Mol Pathol Pharmacol 1995 90 3 373-388 Study conducted in rats demonstrating the efficacy of lanthanum chloride as an intestinal phosphate binder.
21. 366789 Lanthanum carbobate: A novel non-calcium containing phosphate binder in CAPD patients. Hutchinson AJ, Speake M, Dewberry K, Fox JS Perit Dial Int 1998 18 S38
22. 366791 Combined report on regular dialysis and transplantation in Europe, XX, 1989. Fassbinder W, Brunner FP, Brynger H, Ehrich JH, Geerlings W, Raine AE, Rizzoni G, Selwood NH, Tufveson G, Wing AJ Nephrol Dial Transplant 1991 6 Suppl 1 5-35 Provides data on the effects of parathyroidectomy during the late 1980s, reportig no improvement in medical control of secondary hyperparathyroidism in chronic renal failure.
23. 382415 A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients [see comments]. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E Am J Kidney Dis 1999 33 4 694-701 Phase III trial demostrating the similar phosphate-lowering capacity of sevelamer and calcium acetate, although significantly lower hypercalcemic episodes in patients treated with sevelamer is reported.
24. 401854 First filing for Foznol (lanthanum carbonate) in Europe. Shire Pharmaceuticals Group Plc Press Release 2001 March 14
25. 401901 Shire files for European approval of Foznol licensed from AnorMED. AnorMED Inc Press Release 2001 March 14
26. 424603 Healthy Mid-caps, Pan-European opportunities. Blum H Deutsche Banc Alex Brown - Europe 2001 September 25
27. 425705 AnorMED announces positive US phase III clinical data indicate Foznol is effective and well-tolerated. AnorMED Inc Press Release 2001 October 15
28. 425842 Pharma/Biotechs: Flight to quality. Herrmann M Ing Barings 2001 October 01
29. 449854 Foznol NDA submitted to FDA. Shire Pharmaceuticals Group Plc Press Release 2002 April 30
30. 450140 Successful ADDERALL XR launch provides Shire with strong platform for mid to long term growth. Shire Pharmaceuticals Group Plc Press Release 2002 May 01
31. 453948 Fosrenol renal bone disease study results. Shire Pharmaceuticals Group Plc Press Release 2002 June 07
32. 454144 Fosrenol, a treatment for kidney disease, submitted for approval in Canada. AnorMED Inc Press Release 2002 June 10
33. 468945 Fosrenol reduces damaging high levels of phosphate in end-stage kidney disease patients. Shire Pharmaceuticals Group Plc Press Release 2002 November 03
34. 469316 Shire Pharmaceuticals Group plc: Third quarter 2002 results in line with expectations. Shire Pharmaceuticals Group Plc Press Release 2002 November 06
35. 476097 Safety profile of lanthanum carbonate in hemodialysis patients: Results from a phase III US study. Joy MS, Finn WF Pharmacotherapy 2002 22 10 1353
36. 476101 Results of a randomized, phase III, dose-titration, parallel group study of lanthanum carbonate for reduction and maintenance of serum phosphate in chronic hemodialysis patients. Joy MS, Finn WF Pharmacotherapy 2002 22 10 1353
37. 476102 Management of hyperphosphatemia of chronic kidney disease: Lessons from the past and future directions. Malluche HH, Mawad H Nephrol Dial Transplant 2002 17 7 1170-1175
38. 476104 Fosrenol (lanthanum carbonate) vs. calcium carbonate for the treatment of hyperphosphatemia: A comparison of the effects on bone using biopsy examination. J Am Soc Nephrol 2002 13 Abs 769A
39. 476105 Fosrenol: A novel non-calcium, non-aluminum phosphate binder: Is well tolerated when given during or after food intake. Stewart AJ J Am Soc Nephrol 2002 13 Abs 751A
40. 476123 Low systemic absorption of lanthanum and excellent tolerability during administration of 3 g of lanthanum as Fosrenol for 5 days. Fiddler G J Am Soc Nephrol 2002 13 Abs 751A
41. 476124 Fosrenol (lanthanum carbonate) does not affect the pharmacokinetics of concomitant treatment with warfarin. Fiddler G J Am Soc Nephrol 2002 13 749A-750A
42. 476125 Fosrenol (lanthanum carbonate) does not affect the pharmacokinetics of concomitant treatment with digoxin. Fiddler G J Am Soc Nephrol 2002 13 Abs 749A
43. 476127 Fosrenol, a novel non-calcium, non-aluminum phosphate binder, has a good safety and efficacy profile in the long-term treatment of hyperphosphatemia in hemodialysis patients. Joy MS, Finn WF J Am Soc Nephrol 2002 13 Abs 386A
44. 476128 Administration of a novel phosphate binder, Fosrenol, with food is associated with good tolerability and low systemic absorption. Stewart J, Frazer N J Am Soc Nephrol 2002 13 Abs 386A
45. 476129 Fosrenol (lanthanum carbonate) is well tolerated in patients requiring hemodialysis: Results of a phase I clinical trial. Sack M, Frazer N J Am Soc Nephrol 2002 13 Abs 386A
46. 476130 The novel, non-aluminum, non-calcium phosphate binder, Fosrenol, is an effective treatment for hyperphosphatemia and has a good safety profile. Hutchison AJ J Am Soc Nephrol 2002 13 385A-386A
47. 476131 The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients. Sikole A, Spasovski G, Gelev S, Grozdanovski R, Amitov V, D'Haese P, De Broe M Nephrol Dial Transplant 2002 17 1 14-17
48. 476132 An assessment of the effects of lanthanum on bone in a chronic renal failure (CRF) rat model. Behets GJ, Dams G, Damment S, D'Haese PC, De Broe ME J Am Soc Nephrol 2001 12 Abs 740A
49. 476133 Results of a randomized, phase III, dose-titration, parallel group study of lanthanum carbonate for reduction and maintenance of serum phosphate in chronic hemodialysis patients. Joy MS, Finn WF J Am Soc Nephrol 2001 12 Abs 388A
50. 476134 An assessment of the effects of lanthanum on bone in a chronic renal failure rat model. Behets GJ, Dams G, D'Haese PC, Damment S, De Broe ME Nephrol Dial Transplant 2001 16 6 Abs 27
51. 476135 Lanthanum carbonate: A novel non-calcemic phosphate binder in dialysis patients. Albaaj F, Hutchison AJ J Am Soc Nephrol 2000 11 Abs 557A
52. 476137 Lanthanum carbonate: A novel non-calcemic phosphate binder in dialysis patients. Hutchison AJ Nephrol Dial Transplant 2000 15 9 Abs 113
53. 476141 Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis. Finn WF, Joy MS, Hladik GA J Am Soc Nephrol 1999 10 Abs 261A
54. 478278 AnorMED Inc - Presentation at the 1st Annual BioPartnering North America Conference. AnorMED Inc Company Presentation 2003 February 09-11
55. 480167 Shire Pharmaceuticals Group reports strong growth in challenging year produces revenues in excess of $1 billion. Shire Pharmaceuticals Group Plc Press Release 2003 February 27
56. 480453 Shire receives approvable letter from FDA for Fosrenol; Positive step for treatment related to kidney disease in the United States. Shire Pharmaceuticals Group Plc Press Release 2003 March 03
57. 480454 AnorMED announces approvable letter from FDA for Fosrenol. AnorMED Inc Press Release 2003 March 03
58. 480527 FDA approvable letter for Fozrenol - Close but no cigar! Brown MJ, Hall M, Jain S, Yeoh B HSBC 2003 March 03
59. 480814 Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Chertow GM, Burke SK, Raggi P Kidney Int Suppl 2002 62 1 245-252
60. 480816 An open-label, crossover study of a new phosphate-binding agent in hemodialysis patients: Ferric citrate. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH Nephrol Dial Transplant 2002 17 2 265-270
61. 480817 Incorporation of 140-lanthanum into bones, teeth and hydroxyapatite. Fernandez-Gavarron F, Huque T, Rabinowitz JL, Brand JG Bone Miner 1988 3 4 283
62. 480818 Cytotoxicity of the rare earth metals cerium, lanthanum, and neodymium in vitro: Comparisons with cadmium in a pulmonary macrophage primary culture system. Palmer RJ, Butenhoff JL, Stevens JB Environ Res 1987 43 1 142-156
63. 480819 Neurotoxicity of lanthanum chloride in newborn chicks. Basu A, Chakrabarty K, Chatterjee GC Toxicol Lett 1982 14 1-2 21-25
64. 480822 Parathyroidectomy in patients on renal replacement therapy: An epidemiologic study. Malberti F, Marcelli D, Conte F, Limido A, Spotti D and Locatelli F J Am Soc Nephrol 2001 12 6 1242-1248
65. 480823 Safety profile of lanthanum carbonate in hemodialysis patients; Results from a phase III US study. Joy MS, Finn WF J Am Soc Nephrol 2001 12 388A
66. 480824 Effects of lanthanum in cellular systems. A review. Das T, Sharma A, Talukder G Biol Trace Elem Res 1998 18 201-228
67. 481217 Effects of the phosphate binder Renagel (sevelamer) on biochemical parameters and bone histology in a chronic renal failure (CRF) rat model. Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC J Am Soc Nephrol 2001 12 A3863
68. 484773 Long-term treatment with Fosrenol controls harmful phosphate in end-stage kidney disease patients. Shire Pharmaceuticals Group Plc Press Release 2003 April 04
69. 489467 Fosrenol shows promise. Shire Pharmaceuticals Group Plc Press Release 2003 May 14
70. 489502 A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G et al Kidney Int 2003 63 85 73-78